Compare Hafnia Limited Common Shares (HAFN) vs Vertex Pharmaceuticals Incorporated (VRTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Hafnia Limited Common Shares vs Vertex Pharmaceuticals Incorporated — how do they compare? Hafnia Limited Common Shares trades at $10.13 (market cap $5.67B), while Vertex Pharmaceuticals Incorporated trades at $505.79 (market cap $126.35B). The key difference: Vertex Pharmaceuticals Incorporated is far larger — about 22.3× Hafnia Limited Common Shares's market cap, and Hafnia Limited Common Shares pays a 10.44% dividend while Vertex Pharmaceuticals Incorporated pays none. Which is the better fit depends on your goals — on Pluang, investors hold Hafnia Limited Common Shares for 0 Days and Vertex Pharmaceuticals Incorporated for 120 Days on average.
| HAFN | VRTX | |
|---|---|---|
Market Cap | $5.67B | $126.35B |
Volume | 3,240,007 | 2,089,984 |
Sector | Industrials | Health |
52-Week High | $10.92 | $557.96 |
52-Week Low | $5.21 | $407.90 |
Typical Hold Time | 0 Days | 120 Days |
Enterprise Value | $6.29B | $120.48B |
Dividend Yield | 10.44% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
HAFN trades at $10.85, down 0.64% on the day, with a neutral technical signal. The company shows strong fundamentals, with a P/E of 8.35 and net income margin of 24.7%. Recent earnings have consistently beaten expectations, and analysts maintain a 100% buy rating. Key developments include a CEO transition and strategic acquisitions.
Outlook is positive due to robust profitability and growth projections, with 2026 revenue expected to reach $2.7B. Risks include market volatility and execution of new strategies. The stock presents a value opportunity with upside potential, supported by strong cash flow and institutional confidence.
Vertex Pharmaceuticals (VRTX) trades at $485.22, down 4.3% amid a bearish technical signal, though fundamentals remain strong with 2025 revenue of $12.0B and net income of $3.95B. The company maintains dominant cystic fibrosis market position and shows positive Phase II data for kidney disease drug inaxaplin. Analyst consensus is strongly bullish with 85.7% buy ratings and $573.50 price target, representing 18% upside potential from current levels.
Vertex presents a compelling growth story with robust profitability (35% net margin) and expanding pipeline, though recent earnings misses and competitive pressures warrant caution. The stock's current dip may offer entry opportunity for long-term investors, with key catalysts including regulatory decisions and pipeline advancements expected in early 2027.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Hafnia Limited Common Shares
Hafnia Limited owns and operates a fleet of product and chemical tankers that transport refined oil products, vegetable oils, and chemicals for oil and chemical companies worldwide, across the Long Range, Medium Range, and Handy tanker segments, headquartered in Singapore.
Read more on HAFN →About Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio for cystic fibrosis, where Vertex therapies remain the standard of care globally. In addition to its focus on cystic fibrosis, Vertex is diversifying its pipeline through gene-editing therapies such as CTX001 for beta-thalassemia and sickle-cell disease, small-molecule inhibitors targeting acute and chronic pain using non-opioid treatments, and small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.
Read more on VRTX →
